Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Immunocore Holdings Ltd

IMCR
Current price
51.97 USD -0.21 USD (-0.40%)
Last closed 52.64 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 602 432 000 USD
Yield for 12 month -10.50 %
Week
Month
Year
IMCR
21.11.2021 - 28.11.2021

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. Address: 92 Park Drive, Abingdon, United Kingdom, OX14 4RY

Analytics

WallStreet Target Price

79.96 USD

P/E ratio

Dividend Yield

Current Year

+182 531 519 USD

Last Year

+33 677 730 USD

Current Quarter

+65 384 576 USD

Last Quarter

+60 655 471 USD

Current Year

+181 954 985 USD

Last Year

+33 677 730 USD

Current Quarter

+65 105 198 USD

Last Quarter

+59 530 340 USD

Key Figures IMCR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -52 709 000 USD
Operating Margin TTM -1.36 %
PE Ratio
Return On Assets TTM -7.73 %
PEG Ratio
Return On Equity TTM -18.44 %
Wall Street Target Price 79.96 USD
Revenue TTM 191 855 008 USD
Book Value 5.9 USD
Revenue Per Share TTM 3.96 USD
Dividend Share
Quarterly Revenue Growth YOY 25 %
Dividend Yield
Gross Profit TTM 54 113 000 USD
Earnings Share -1.41 USD
Diluted Eps TTM -1.41 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -67.7 %
Profit Margin -28.18 %

Dividend Analytics IMCR

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IMCR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation IMCR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 11.6606
Price Sales TTM 13.5646
Enterprise Value EBITDA -56.218
Price Book MRQ 7.0463

Financials IMCR

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators IMCR

For 52 weeks

42.21 USD 67.43 USD
50 Day MA 48.28 USD
Shares Short Prior Month 3 684 316
200 Day MA 55.01 USD
Short Ratio 15.53
Shares Short 4 152 088
Short Percent 8.42 %